Page 1 | Search Results | Blood | American Society of Hematology

1-5 of 5

Sort by

Sort Order Select

Journal Articles

Clinical Characteristics, Treatment and Outcomes for Patients with Myelodysplastic Syndromes and Chromosome 5q Abnormalities in the Republic of Ireland

Su Wai Maung, MBBS, MRCP(UK), Cian McEllistrim, MRCPI, Amjad Hayat, MBBS, MRCP, FRCPath, PhD, Margaret Murray, FRCPath, Michael O'Dwyer, MD, Patrick Thornton, FRCPath, Emma Groarke, MRCPI, Denis O'Keeffe, MD MRCPath, Maeve Leahy, MD MRCPath, Aine Burke, MRCP,MD, Peter O'Gorman, Carmel Weldon, M.Sc, MRCPI, Gerard Crotty, MD FRCPath, Meegahage Ratnakanthi Perera, MDMRCPath,MBBS, Cathie Burke, RN, Johnny McHugh, FRCPath, Helen Enright, MD FRCPI, FRCPath, Ronan Desmond, MD FRCPath

Blood (2015) 126 (23): 5258.

https://doi.org/10.1182/blood.V126.23.5258.5258

Published: 2015

Journal Articles

A Single Centre Analysis of Spectra Optia Stem Cell Collection Data from Multiple Myeloma and Lymphoma Patients, with and without Plerixafor

Joy Buckley, M.Sc. B.Sc., Janusz Krawczyk, MD MRCP, Fionnuala Ni Chonchubhair, MSc, BSc., Nelly Besson, PhD, Margaret Tarpey, MSc. BSc., Margaret Murray, MD, F.R.C.Path., F.R.C.P.I. F.F.Path, M.R.C.P. (U.K.), Michael C O'Dwyer, MD FRCPI, FRCPath, Amjad Hayat, MBBS, MRCP, MRCPath, PhD

Blood (2014) 124 (21): 3848.

https://doi.org/10.1182/blood.V124.21.3848.3848

Published: 2014

Journal Articles

Cybord Is An Active, Well Tolerated, Cost-Effective Induction Regimen In Newly Diagnosed Multiple Myeloma – a Single Centre Experience

Janusz Krawczyk, MD, MRCP, Sahar Khan, Bushra Ahsan, Larissa Higgins, Enda McGowan, Safa Eltom, Khalid Awad Saeed, Carmelita Gibbons, Karen Maloney, Teresa Meenaghan, Geraldine Walpole, Catriona Collins, Robert Snedker, Moutaz Abdelrahmen, Amjad Hayat, MBBS, PhD, Andrew Hodgson, MBBS, BSc, FRCP, FRCPath, Margaret Murray, MD, MRCPath, Michael E O'Dwyer, MD, FRCPI, FRCPath

Blood (2013) 122 (21): 5396.

https://doi.org/10.1182/blood.V122.21.5396.5396

Published: 2013

Journal Articles

Laborartory Medicine Resource Management in Times of Austerity: An Opportunity to Rationalize Services Using Vitamin B12 and Folate Testing As an Example

Maeve P Crowley, MB BCh BAO BSc MRCPI, Margaret Murray, MD, MRCPath, Amjad Hayat, MBBS, PhD

Blood (2012) 120 (21): 4229.

https://doi.org/10.1182/blood.V120.21.4229.4229

Published: 2012

Journal Articles

Bortezomib, Adriamycin Dexamethasone (PAD) Combination Therapies or Patients with Relapsed or Refractory Myeloma Previously Treated with VAD or VAD like Therapy.

Treen C. Morris, Mary Drake, Paul J. Kettle, Aishleen Brunton, James D. Cavenagh, Heather E. Oakervee, Michael O’Dwyer, Margaret Murray, Tanya O’Shea, Gordon Cook

Blood (2006) 108 (11): 5117.

https://doi.org/10.1182/blood.V108.11.5117.5117

Published: 2006

NARROW

Clinical Characteristics, Treatment and Outcomes for Patients with Myelodysplastic Syndromes and Chromosome 5q Abnormalities in the Republic of Ireland

A Single Centre Analysis of Spectra Optia Stem Cell Collection Data from Multiple Myeloma and Lymphoma Patients, with and without Plerixafor

Cybord Is An Active, Well Tolerated, Cost-Effective Induction Regimen In Newly Diagnosed Multiple Myeloma – a Single Centre Experience

Laborartory Medicine Resource Management in Times of Austerity: An Opportunity to Rationalize Services Using Vitamin B12 and Folate Testing As an Example

Bortezomib, Adriamycin Dexamethasone (PAD) Combination Therapies or Patients with Relapsed or Refractory Myeloma Previously Treated with VAD or VAD like Therapy.

Email alerts

ASH Publications

American Society of Hematology

Clinical Characteristics, Treatment and Outcomes for Patients with Myelodysplastic Syndromes and Chromosome 5q Abnormalities in the Republic of Ireland

A Single Centre Analysis of Spectra Optia Stem Cell Collection Data from Multiple Myeloma and Lymphoma Patients, with and without Plerixafor

Cybord Is An Active, Well Tolerated, Cost-Effective Induction Regimen In Newly Diagnosed Multiple Myeloma – a Single Centre Experience

Laborartory Medicine Resource Management in Times of Austerity: An Opportunity to Rationalize Services Using Vitamin B12 and Folate Testing As an Example

Bortezomib, Adriamycin Dexamethasone (PAD) Combination Therapies or Patients with Relapsed or Refractory Myeloma Previously Treated with VAD or VAD like Therapy.

Email alerts

ASH Publications

American Society of Hematology

This Feature Is Available To Subscribers Only